2 Firms Steer Merck's $300M Immune Design Deal
Merck & Co. Inc., guided by Gibson Dunn & Crutcher LLP, said Thursday it has agreed to acquire late-stage immunotherapy company Immune Design, advised by Cooley LLP, for approximately $300 million....To view the full article, register now.
Already a subscriber? Click here to view full article